Clinical trials: Recurrent Thromboembolic Disease
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism, Venous Thromboses
Leiden Thrombosis Recurrence Risk Prevention
The goal of this clinical trial is to evaluate tailored duration of long-term anticoagulant treatment after a first venous thromboembolism based on individualized risk assessments of recurrent VTE and major bleeding risks.
- Conditions
- Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- L-TRRiP (NCT06087952)
- Testing
- Randomised treatment advice (discontinue vs continue after 3 months), VTE-BLEED score, L-TRRiP score
- Where
- 19 sites in Netherlands
- Volunteers
- 608 people
- Sponsor
- Leiden University Medical Center
Lymphoma, Thromboembolism
Heparin or Enoxaparin in Patients With Cancer
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor.
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004875
- Testing
- enoxaparin, heparin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Venous Thrombosis and Pulmonary Embolism
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
- Trial name
- COSIMO (NCT02742623)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- 10 sites in Australia, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Bayer
Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of…
- Trial name
- PADIS TVP (NCT00740493)
- Testing
- warfarin
- Where
- 14 sites in France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Brest
Previous Vka Treatment, Previous Proximal VTE
Echo Doppler (ED )Score and D-dimer (DD) Level in the Evaluation of VTE Recurrence After Anticoagulant Treatment Cessation
The purpose of this trial is to perform a prospective multicentric study to determine predictive ED score and D-dimer level in the evaluation of the thromboembolic event recurrence after anticoagulant treatment cessation.
- Trial name
- VAPRED (NCT00860106)
- Testing
- ED, DDimers and phone follow up
- Where
- 16 sites in France
- Volunteers
- 222 people
- Sponsor
- University Hospital, Grenoble
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00031837
- Testing
- dalteparin, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 13 sites in United States
- Volunteers
- 400 people
- Sponsor
- Gary Morrow
Idiopathic Venous Thromboembolism
Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism
The main objective of this study is to verify whether a new clinical decision rule identifying patients diagnosed with unprovoked blood clots who have a low risk of recurrence can safely stop oral anticoagulant therapy after 5-7…
- Trial name
- REVERSEII (NCT00967304)
- Testing
- Application of the"Men continue and HER DOO2" rule
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 2,779 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism, Anticoagulant-induced Bleeding
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Venous thromboembolism affects around 10 million people per year worldwide, however, despite its high incidence, there is no systematic review or randomized trial focused on the treatment of patients with recurrent deep vein…
- Conditions
- Venous Thromboembolism, Anticoagulant-induced Bleeding, Venous Thromboses, Pulmonary Embolism
- Trial name
- NCT05515120
- Testing
- Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet
- Where
- Mexico
- Volunteers
- 58 people
- Sponsor
- Instituto Mexicano del Seguro Social
Deep Venous Thrombosis
D-Dimer Guided Oral Anticoagulant Treatment (OAT)
This clinical trial will investigate the hypothesis that D-Dimer testing can be successfully used to tailor the duration of OAT in patients after an unprovoked episode of deep venous thrombosis (DVT) using a prospective…
- Trial name
- DDOAT2006 (NCT00895505)
- Testing
- Phenprocoumon, Warfarin-Natrium
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital, Bonn
Cancer, Venous Thromboembolism
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study
Objective: To prospectively evaluate clinical outcomes during guideline-recommended LMWH dose escalation for recurrent VTE during LMWH or DOAC treatment for cancer-associated thrombosis.
- Conditions
- Cancer, Venous Thromboembolism, Recurrence
- Trial name
- REDUCE (NCT05229471)
- Where
- 9 sites in Italy, Netherlands and 1 more
- Volunteers
- 220 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Venous Thromboembolism
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein…
- Trial name
- RE-SONATE (NCT00558259)
- Testing
- dabigatran etexilate 150 mg twice daily (BID)
- Where
- 147 sites in United States, Australia and 19 more
- Volunteers
- 1,353 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism, Neoplasms
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Background Patients with cancer and a first deep venous thrombosis of the leg or pulmonary embolism (venous thromboembolism, VTE) are generally treated with low molecular weight heparin (LMWH)injections for 6 months, since this…
- Trial name
- Longheva (NCT01164046)
- Testing
- low molecular weight heparin, vitamin K antagonists
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- University Medical Center Groningen
Cancer-associated Thrombosis
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism…
- Trial name
- CAN-CATCH (NCT06894576)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Ottawa Hospital Research Institute